• Publications
  • Influence
Marine organisms as a source of new anticancer agents.
TLDR
Examples of marine-derived experimental agents that are currently undergoing preclinical and early clinical evaluation are briefly discussed and a summary of the available information on the results of phase I and II trials of agents such as aplidine, ecteinascidin-734 (ET- 734), dolastatin 10 and bryostatin 1 is presented. Expand
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.
TLDR
The inhibitory effect of Yondelis on macrophage viability, differentiation, and cytokine production is likely to contribute to the antitumor activity of this agent in inflammation-associated human tumors. Expand
Antigenic profiles of endothelial and hemopoietic lineages in murine intraembryonic hemogenic sites.
TLDR
The present report focuses on the antigenic characterisation of immature hemopoietic progenitors in order to trace back the intraembryonic precursors at earlier developmental stages. Expand
Progress in the development and acquisition of anticancer agents from marine sources.
TLDR
Some of the technical strategies that are being employed to collect and identify novel marine products with potential antitumoral properties are reviewed, and a summary of the available clinical trial information of agents with promising activity is provided. Expand
Kahalalide F Induces Necrosis-Like Cell Death that Involves Depletion of ErbB3 and Inhibition of Akt Signaling
TLDR
It is found that KF efficiently inhibited the phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway in sensitive cell lines and that ectopic expression of a constitutively active Akt mutant reduced KF cytotoxicity in this cell line. Expand
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
TLDR
Trabectedin administered as a 3-hour infusion at 1,300 microg/m(2) is a safe new drug with promising activity in relapsed ovarian cancer, showing a 43% objective response rate in patients with platinum-sensitive disease, which favorably compares with other salvage treatments and warrants additional development either alone or in combination. Expand
Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.
TLDR
The results suggest that pretreatment with high-dose dexamethasone effectively protects rats against yondelis-mediated hepatic damage by decreasing hepatic exposure to yONDelis, perhaps linked to induction of metabolism by cytochrome P450 enzymes. Expand
Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.
TLDR
The combination of PM02734 and erlotinib was more effective in inhibiting AKT than either single agent alone in H322 cells and provided a rational basis for an ongoing clinical trial to explore this combination in patients with advanced malignant solid tumours. Expand
In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
TLDR
The data from the cloning assay indicate that the duration of exposure to ET-743 is an important factor in human tumors, and long-term exposure to the novel compound may be preferred in future clinical trials. Expand
...
1
2
3
4
5
...